Editorial Perspective
Thyroid diseases need to be considered as contributing to the clinical picture in patients with a host of systemic and dermatologic disorders, many of which are classified as autoimmune. Imagine the following scenario: A 46-year-old woman with a known history of systemic lupus erythematosus complains of the recent development of leg weakness. The clinician needs to determine if this could be due to the lupus itself, a reaction to treatment (such as a steroid-induced myopathy), or if there is a concurrent pathologic process. Considering thyroid disease in this context should be routine; however, it is all too often forgotten as a diagnostic possibility. It is also essential to consider if a patient's medications may be affecting thyroid function. For example, if a patient with cutaneous T-cell lymphoma (CTCL) develops xerosis to the point of being considered as having an acquired ichthyosis, is the ichthyotic skin secondary to the lymphoma or to bexarotene-induced central hypothyroidism? This chapter emphasizes those disorders and medications that merit screening for thyroid disease in the appropriate clinical context, utilizing thyroid function studies or thyroid autoantibodies. The ability to treat thyroid disease should provide an impetus for assessing the thyroid status in patients with the maladies discussed in this chapter. Assessing thyroid function should be considered standard practice in patients with a personal or family history of any autoimmune disease.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ai J, Leonhardt JM, Heymann WR. Autoimmune thyroid diseases: etiology, pathoegenesis, and der-matologic manifestations. J Am Acad Dermatol 2003;48:641–659.
Jameson JL, Weetman AP. Disorders of the thyroid gland. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, ed. Harrison's Principles of Internal Medicine. New York: McGraw-Hill; 2001:2060–2071.
Betterle C, Lazzarotto F, Presotto F. Autoimmune polyglandular syndrome type 2: the tip of an iceberg?. Clin Exp Immunol 2004;137:225–233.
Betterle C, Dal Pra C, Mantero F, Zanchetta R. Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoanti-gens, and their applicability in diagnosis and disease prediction. Endocr Rev 2002;23:327–364.
Majeroni BA, Patel P. Autoimmune polyglandular syndrome, type II. Am Fam Physician 2007;75:667–670.
Neufeld M, Blizzard RM. Polyglandular autoimmune diseases. In: Pinchera A, Doniach D, Fenzi GF, Baschieri L, eds. Symposium on Autoimmune Aspects of Endocrine Disorders. New York: Academic Press; 1980:357–365.
Amerio P, Tracanna M, De Remigis P, et al. Vitiligo associated with other autoimmune diseases: polyg-landular autoimmune syndrome types 3B+C and 4. Clin Exp Dermatol 2006;31:746–749.
Wollina U, Schreiber G. Polyglandular autoimmune syndrome type II (Schmidt's syndrome) in patients with autoimmune connective tissue disorders. J Eur Acad Dermatol Venereol 2003;17:371–372.
Biro E, Szekanecz Z, Czirjak L, et al. Association of systemic and thyroid autoimmune diseases. Clin Rheumatol 2006;25:240–245.
James WD, Berger TG, Elston DM. Andrews' Diseases of the Skin, Clinical Dermatology. 10th ed. Philadelphia: Saunders; 2006.
Gill JM, Quisel AM, Rocca PV, et al. Diagnosis of systemic lupus erythematosus. Am Fam Physician 2003;68:2179–2185.
Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for classification of systemic lupus erythema-tosus. Arthritis Rheum 1982;25:1271–1277.
Petri M. Treatment of systemic lupus erythematosus: an update. Am Fam Physician 1998;57:2753–2760.
Callen J P. Discoid lupus erythematosus in a patient with vitiligo and autoimmune thyroiditis. Int J Dermatol 1984;23:203–204.
Chan AT, Al-Saffar Z, Bucknall RC. Thyroid disease in systemic lupus erythematosus and rheumatoid arthritis. Rheumatology 2001;40:353–354.
Goh KL, Wang F. Thyroid disorders in systemic lupus erythematosus. Ann Rheum Dis 1986;45:579–583.
Jakez-Ocampo J, Richaud-Patin Y, Perez-E B, et al. Systemic lupus erythematosus with thyroidi-tis: a therapeutic dilemma?. Clin Exp Rheumatol 2002;20:114–115.
McDonagh JE, Isenberg DA. Development of additional autoimmune diseases in a population of patients with systemic lupus erythematosus. Ann Rheum Dis 2000;59:230–232.
Pyne D, Isenberg DA. Autoimmune thyroid disease in systemic lupus erythematosus. Ann Rheum Dis 2002;61:70–72.
van deer Meer-Roosen CH, Maes EP, Faber WR. Cutaneous lupus erythematosus and autoimmune thyroiditis. Br J Dermatol 1979;101:91–92.
Laxer RM, Zulian F. Localized scleroderma. Curr Opin Rheumatol 2006;18:606–613.
Varga J, Abraham D. Systemic sclerosis: a proto-typic multisystem fibrotic disorder. J Clin Invest 2007;117:557–567.
Haustein UF. Scleroderma and pseudo-scleroderma: uncommon presentations. Clin Dermatol 2005;23:480–490.
Costner MI, Grau RH. Update on connective tissue diseases in dermatology. Semin Cutan Med Surg 2006;25:207–220.
Subcommittee for Scleroderma Criteria of the American Rhuematism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (sclero-derma). Arthritis Rheum 1980;23:581–590.
Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005;35:35–42.
Kucharz EJ. Thyroid disorders in patients with progressive systemic sclerosis: a review. Clin Rheumatol 1993;12:159–161.
Innocencio RM, Romaldini JH, Ward LS. Thyroid autoantibodies in autoimmune diseases. Medicina 2004;64:227–230.
Innocencio RM, Romaldini JH, Ward LS. High prevalence of thyroid autoantibodies in systemic sclerosis and rheumatoid arthritis but not in the antiphos-pholipid syndrome. Clin Rheumatol 2003;22:494.
Marasini B, Massarotti M, Cossutta R. Thyroid function, pulmonary arterial hypertension and scle-roderma. Am J Med 2005;118:322–323.
Yanai-Landau H, Amital H, Bar-Dayan Y, et al. Autoimmune aspects of primary pulmonary hypertension. Pathobiology 1995;63:354–355.
Fox RI, Liu AY. Sjögren's syndrome in dermatology. Clin Dermatol 2006;24:393–413.
Vitali C. Classification criteria for Sjögren's syndrome. Ann Rheum Dis 2003;62:94–95.
Lazarus MN, Isenberg DA. Development of additional autoimmune diseases in a population of patients with primary Sjögren's syndrome. Ann Rheum Dis 2005;64:1062–1064.
Tunc R, Gonen MS, Acbay O, et al. Autoimmune thyroiditis and anti-thyroid antibodies in primary Sjögren's syndrome: a case-control study. Ann Rheum Dis 2004;63:575–577.
Bertram U, Halberg P. Organ antibodies in Sjögren's syndrome. Acta Allergol 1965;20:472–483.
D'Arbonneau F, Ansart S, Le Berre R, et al. Thyroid dysfunction in primary Sjögren's syndrome: a long-term follow-up study. Arthritis Rheum 2003;49:804–809.
Dalakas MC, Hohlfeld R. Polymyositis and dermato-myositis. Lancet 2003;362:971–982.
Kimyai-Asadi A, Tausk FA, Nousari HC. A patient with dermatomyositis and linear streaks on the back. Arch Dermatol 2000;136:665–670.
Choy EH, Hoogendijk JE, Lecky B, et al. Immuno-suppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev 2005;3:CD003643.
Lee JH, Kim SI. A case of dermatomyositis associated with papillary cancer of the thyroid gland. Clin Rheumatol 2005;24:437–438.
Chamberlain MJ, Whittaker SRF. Hashimoto's disease, dermatomyositis and ovarian carcinoma. Lancet 1963;1:1398–1399.
Catherine LH, Yuqing Z, Bardur S, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001;357:96–100.
Antti A, Eero P, Heikki I. Elevated cancer incidence in patients with dermatomyositis: a population based study. J Rheumatol 1995;22:1300–1303.
Hatada T, Aoli I, Ikeda H, et al. Dermatomyositis and malignancy: case report and review of the Japanese literature. Tumori 1996;82:273–275.
Archambeaud MF, Bernard P, Laroumagne G, et al. Dermatomyositis associated with cancer of the thyroid. Favorable course after iodine-131 irradiation. Presse Med 1986;15:1928.
Philippe C, Slim S, Isabelle T, et al. Thyroid plasma-cytoma with dermatomyositis and palmar fasciitis. J Rheumatol 1989;16:997–999.
Gamsky TE, Chan MK. Coexistent dermatomy-ositis and autoimmune thyroiditis. West J Med 1988;148:213–214.
Kato H, Uyeki Y, Kitajima Y, et al. A case of dermat-omyositis and Hashimoto's thyroiditis. J Dermatol 1988;15:273–275.
Kobayashi T, Asakawa H, Komoike Y, et al. A patient with Graves' disease, myasthenia gravis and polymyositis. Thyroid 1997;7:631–632.
Go T, Mitsuyoshi I. Juvenile dermatomyositis associated with subclinical hypothyroidism due to auto-immune thyroiditis. Eur J Pediatr 2002;161:358–359.
Swanton J, Isenberg D. Mixed connective tissue disease: still crazy after all these years. Rheum Dis Clin North Am 2005;31:421–436.
Venables PJ. Mixed connective tissue disease. Lupus 2006;15:132–137.
Kim P, Grossman JM. Treatment of mixed connective tissue disease. Rheum Dis Clin North Am 2005;31:549–565.
Mirante A, Salgado M, Moura L, et al. Hashimoto's thyroiditis and mixed connective tissue disease in an 11 year-old girl. J Pediatr Endocrinol 1997;10:77–8.
Inoue K, Okajima T, Tanaka E, et al. A case of Graves' disease associated with autoimmune hepatitis and mixed connective tissue disease. Endocrinol J 1999;46:173–177.
Hirasaki S, Koide N, Ogawa H, et al. Mixed connective tissue disease associated with idiopathic portal hypertension and chronic thyroiditis. J Gastroenterol 1997;32:808–811.
Aqel NM, Amr SS, Najjar MM, et al. Kikuchi's lymphadenitis developing in a patient with mixed connective tissue disease and Hashimoto's thyroiditis. Br J Rheumatol 1997;36:1236–1238.
Hata T, Kavanaugh A. Rheumatoid arthritis in dermatology. Clin Dermatol 2006;24:430–437.
Sayah A, English JC 3rd. Rheumatoid arthritis: a review of the cutaneous manifestations. J Am Acad Dermatol 2005;53:191–209.
Mewar D, Wilson AG. Autoantibodies in rheumatoid arthritis: a review. Biomed Pharmacother 2006;60:648–655.
Somers EC, Thomas SL, Smeeth L, et al. Autoimmune diseases co-occurring within individuals and within families: a systematic review. Epidemiology 2006;17:202–217.
Pritchard J, Tsui S, Horst N, et al. Synovial fibroblasts from patients with rheumatoid arthritis, like fibrob-lasts from Graves' disease, express high levels of IL-16 when treated with immunoglobulins against the IGF-1 receptor. J Immunol 2004;173:3564–3569.
McCuin JB, Hanlon T, Mutasim DF. Autoimmune bullous disease: diagnosis and management. Dermatol Nurs 2006;18:20–25.
Fassihi H, Wong T, Wessagowit V, et al. Target proteins in inherited and acquired blistering skin disorders. Clin Exp Dermatol 2006;31:252–259.
Stanley JR, Amagai M. Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome. N Engl J Med 2006;355:1800–1810.
Nicolas ME, Krause PK, Gibson LE, et al. Dermatitis herpetiformis. Int J Dermatol 2003;42:588–600.
Wu H, Schapiro B, Harrist TJ. Noninfectious vesicu-lobullous and vesiculopustular diseases. In: Elder DE, Elenitsas R, Johnson BL Jr, Murphy GF, eds. Lever's Histopathology of the Skin. Philadelphia: Lippincott Williams and Wilkins; 2005:243–292.
Callen JP. Internal disorders associated with bullous disease of the skin. A critical review. J Am Acad Dermatol 1980;3:107–119.
Shornick JK, Black MM. Secondary autoimmune diseases in herpes gestationis (pemphigoid gesta-tionis). J Am Acad Dermatol 1992;26:563–566.
Lynfield YL, Green K, Gopal R, et al. Bullous pem-phigoid and multiple autoimmune diseases. Alopecia universalis, bullous pemphigoid, hypothyroidism, rheumatoid arthritis, and neutropenia in one patient. J Am Acad Dermatol 1983;9:257–261.
Holmes RC, Black MM. Herpes gestationis. A possible association with autoimmune thyrotoxicosis (Graves' disease). J Am Acad Dermatol 1980;3:474–477.
Fiorucci MC, Cozzani E, Casu M, et al. Bullous pemphigoid and Graves' disease: an association between skin and thyroid autoimmunity. Acta Derm Venereol 2005;85:560–561.
Smith WD, Jones MS, Stewart TW, et al. Bullous pemphigoid occurring in psoriatic plaques in association with Hashimoto's thyroiditis. Clin Exp Dermatol 1991;16:389–391.
Tirado-Sanchez A, Montes-de-Oca G. Coexistence of bullous pemphigoid, vitiligo, and thyroid disease: a multiple autoimmune syndrome?. Dermatol Online J 2005;11:20.
Suehisa E, Toku M, Akita N, et al. Study on an antibody against F1F2 fragment of human factor V in a patient with Hashimoto's disease and bullous pemphigoid. Thromb Res 1995;77:63–68.
Bartalena L, Bogazzi F, Chiovato L, et al. Graves' hyperthyroidism and ophthalmopathy associated with pemphigus vulgaris: onset of thyroid autoimmune disease during chronic low-dose glucocorti-coid therapy. J Endocrinol Invest 1997;20:155–157.
Iino Y, Hara H, Suda T, et al. Co-existence of pemphigus vulgaris and Hashimoto's thyroiditis. Eur J Dermatol 2005;15:40–42.
Kahana M, Levy A, Schewach-Millet M, et al. Pemphigus foliaceus coexisting with toxic, multin-odular goiter. Int J Dermatol 1986;25:465–466.
Khare AK, Singh G. Pemphigus vulgaris with myxo-edema. Indian J Dermatol 1983;28:171–172.
Yancin B, Tamer E, Toy GG, et al. Development of pemphigus vulgaris in a patient with vitiligo and Hashimoto's thyroiditis. J Endocrinol Invest 2005;28:558–560.
Pitoia F, Moncet D, Glorio R, et al. Prevalence of thyroid autoimmunity in patients with pemphigus vulgaris. Medicina 2005;65:307–310.
Khachemoune A, Guldbakke KK, Ehrsam E. Pemphigus foliaceus: a case report and short review. Cutis 2006;78:105–110.
Hamlet KR, Stevens SR, Gushurst C, et al. Juvenile pemphigus vulgaris associated with Graves' disease. J Am Acad Dermatol 1995;33:132–134.
Levine L, Bernstein JE, Soltani K, et al. Coexisting childhood pemphigus foliaceus and Graves' disease. Arch Dermatol 1982;118:602–604.
Gaspari AA, Huang CM, Davey RJ, et al. Prevalence of thyroid abnormalities in patients with dermatitis herpetiformis and in control subjects with HLA-B8/-DR3. Am J Med 1990;88:145–150.
Kaplan RP, Callen JP. Dermatitis herpetiformis: autoimmune disease associations. Clin Dermatol 1991;9:347–360.
Reunala T, Collin P. Disease associated with dermatitis herpetiformis. Br J Dermatol 1997;136:315–318.
Weetman AP, Burrin JM, Mackay D, et al. The prevalence of thyroid autoantibodies in dermatitis herpetiformis. Br J Dermatol 1988;118:377–383.
Zettinig G, Weissel M, Flores J, et al. Dermatitis herpetiformis is associated with atrophic but not with goitrous variant of Hashimoto's thyroiditis. Eur J Clin Invest 2000;30:53–57.
Collin P, Kaukinen K, Valimaki M, et al. Endocrinological disorders and celiac disease. Endocr Rev 2002;23:464–483.
Lutfi RJ, Fridmanis M, Misiunas AL, et al. Association of melasma with thyroid autoimmunity and other thyroidal abnormalities and their relationship to the origin of the melasma. J Clin Endocrinol Metab 1985;61:28–31.
Niepomniszcze H, Amad RH. Skin disorders and thyroid diseases. J Endocrinol Invest 2001;24:628–638.
Gupta AK, Gover MD, Nouri K, et al. The treatment of melasma: a review of clinical trials. J Am Acad Dermatol 2006;55:1048–1065.
Passeron T, Ortonne JP. Physiopathology and genetics of vitiligo. J Autoimmun 2005;25:63–68.
Ongenae K, Beelaert L, van Geel N, et al. Psychosocial effects of vitiligo. J Eur Acad Dermatol Venereol 2006;20:1–8.
Whitton ME, Ashcroft DM, Barrett CW, et al. Interventions for vitiligo. Cochrane Database Syst Rev 2006;1:CD003263.
Rusfianti M, Wirohadidjodjo YW. Dermatosurgical techniques for repigmentation of vitiligo. Intl J Dermatol 2006;45:411–417.
Cunliffe WJ, Hall R, Newell DJ, et al. Vitiligo, thyroid disease and autoimmunity. Br J Dermatol 1968;80:135–139.
Daneshpazhooh M, Mostofizadeh G M, Behjati J, et al. Anti-thyroid peroxidase antibody and vitiligo: a controlled study. BMC Dermatol 2006;6:3.
Hegedus L, Heidenheim M, Gervil M, et al. High frequency of thyroid dysfunction in patients with vitiligo. Acta Derm Venereol 1994;74:120–123.
Kakourou T, Kanaka-Gantenbein C, Papadopoulou A, et al. Increased prevalence of chronic autoimmune (Hashimoto's) thyroiditis in children and adolescents with vitiligo. J Am Acad Dermatol 2005;53:220–223.
Iacovelli P, Sinagra JL, Vidolin AP, et al. Relevance of thyroiditis and of other autoimmune diseases in children with vitiligo. Dermatology 2005;210:26–30.
Soyun C, Hyung-Chul K, Jeong-Hee H. Characteristics of vitiligo in Korean Children. Pediatr Dermatol 2000;17;189–193.
Barton Sterling J, Heymann WR. Potassium iodide in dermatology: a 19th century drug for the 21st century—uses, pharmacology, adverse effects, and contraindications. J Am Acad Dermatol 2000;43:691–697.
Heymann WR. Potassium iodide and the Wollf-Chaikoff effect: relevance for the dermatologist. J Am Acad Dermatol 2000;42:490–492.
Basaria S, Cooper DS. Amiodarone and the thyroid. Am J Med 2005;118:706–714.
Sherman SI, Gopal J, Haugen BR, et al. Central hypothyroidism associated with retin-oid X receptor-selective ligands. N Engl J Med 1999;340:1075–1079.
Alpay K, Kurkcuoglu N. Iododerma: an unusual side effect of iodide ingestion. Pediatr Dermatol 1996;13:51–53.
Soria C, Allegue F, Espana A, et al. Vegetating iodo-derma with underlying systemic diseases: report of three cases. J Am Acad Dermatol 1990;22:418–422.
Dereure O. Drug-induced skin pigmentation. Epidemiology, diagnosis and treatment. Am J Clin Dermatol 2001;2:253–262.
Wilson JS, Podrid PJ. Side effects from amiodar-one. Am Heart J 1991;121:158–171.
Basaria S, Cooper DS. Amiodarone and the thyroid. Am J Med 2005;118:706–714.
Loh KC. Amiodarone-induced thyroid disorders: a clinical review. Postgrad Med J 2000;76:133–140.
Ursella S, Testa A, Mazzone M, et al. Amiodarone-induced thyroid dysfunction in clinical practice. Eur Rev Med Pharmacol Sci 2006;10:269–278.
Govindan R, Crowley J, Schwartzberg L, et al. Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies. J Clin Oncol 2006;24:4848–4854.
Yen WC, Prudente RY, Corpuz MR, et al. A selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) inhibits angiogenesis and metastasis in solid tumours. Br J Cancer 2006;94:654–660.
Duvic M, Martin AG, Kim Y, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001;137:581–593.
Liu S, Ogilvie KM, Klausing K, et al. Mechanism of selective retinoid X receptor agonist-induced hypothyroidism in the rat. Endocrinology 2002;143:2880–2885.
Sherman SI, Gopal J, Haugen BR, et al. Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med 1999;340:1075–1079.
Assaf C, Bagot M, Dummer R, et al. Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. Br J Dermatol 2006;155:261–266.
Gupta A, Eggo MC, Uetrecht J P, et al. Drug-induced hypothyroidism: the thyroid as a target organ in hyper-sensitivity reactions to anticonvulsants and sulfona-mides. Clin Pharmacol Ther 1992;51:56–67.
Oskay T, Karademir A, Erturk OI. Association of anticonvulsant hypersensitivity syndrome with Herpesvirus 6, 7. Epilepsy Res 2006;70:27–40.
Prussick R, Shear NH. Dapsone hypersensitivity syndrome. J Am Acad Dermatol 1996;35:346–349.
Jabbour SA. Cutaneous manifestations of endocrine disorders: a guide for dermatologists. Am J Clin Dermatol 2003;4:315–331.
Carpenter CCJ, Solomon N, Silverberg SG, et al. Schmidt's syndrome (thyroid and adrenal insufficiency): a review of the literature and a report of fifteen new cases including ten instances of coexistent diabetes mellitus. Medicine 1964;43:153–180.
Neufeld M, Maclaren NK, Blizzard RM. Two types of autoimmune Addison's disease associated with different polyglandular autoimmune (PGA) syndromes. Medicine 1981;60:1653–1660.
Caravati CM, Richardson DR, Wood BT, et al. Cutaneous manifestations of hyperthyroidism. Southern Med J 1969;62:1127–1130.
Ghayee HK, Mattern JQ 3rd, Cooper DS. Dirty nails. J Clin Endocrinol Metab 2005;90:2428.
Heymann WR. Advances in the cutaneous manifestations of thyroid disease. Int J Dermatol 1997;36:641–645.
Leonhardt JM, Heymann WR. Thyroid disease and the skin. Dermatol Clin 2002;3:473–481.
Mullin GE, Eastern JS. Cutaneous consequences of accelerated thyroid function. Cutis 1986;37:109–114.
Dilley JJ, Kierland RR, Randall RV, et al. Primary lymphedema associated with yellownails and pleu-ral effusion. JAMA 1968;204:122.
Blumberg M, Connolly DM, Freedberg IM. Regulation of keratin gene expression: the role of the nuclear receptors for retinoic acid, thyroid hormone and vitamin D3. J Invest Dermatol 1992;98:42S–49S.
Hellgren L, Mobacken H. Pustulosis palmaris et plantaris. Acta Derm Venereol 1971;51:284–288.
Eriksson M-O, Hagforsen E, Lundin IP, et al. Palmoplantar pustulosis: a clinical and immu-nohistological study. Br J Dermatol 1998; 138:390–398.
Gimenez-Garcia R, Sanchez-Ramon S, Cuellar-Olmenda LA. Palmoplantar pustulosis: a clinicoepi-demiologic study. The relationship between tobacco use and thyroid function. J Eur Acad Dermatol Venereol 2003;16:276–279.
Rosen K, Lindstedt G, Mobacken H, et al. Thyroid function in patients with pustulosis palmoplantaris. J Am Acad Dermatol 1988; 19:1009–1016.
Rosen K, Mobacken H, Nilson L-A, et al. Increased prevalence of antithyroid antibodies and thyroid diseases in pustulosis palmoplantaris. Acta Derm Venereol 1981;61:237–240.
Miller JJ, Roling D, Spiers E, et al. Palmoplantar keratoderma associated with hypothyroidism. Br J Dermatol 1998;139:741–742.
Salduna MD, Fux C, Albertini R, et al. Acquired palmoplantar keratoderma with hypothyroidism. Medicina 2005;65:47–48.
Aram H. Acquired ichthyosis and related conditions. Int J Dermatol 1984;23:458–461.
Schwartz RA, Williams ML. Acquired ichthyosis: a marker for internal disease. Am Fam Physician 1984;29:181–184.
Brazzelli V, Prestinari F, Barbagallo T, et al. Acquired ichthyosis and hypertrichosis due to autoimmune thyroiditis: therapeutic response to thyroxine replacement. Pediatr Dermatol 2005;22:447–449.
Heymann WR. Cutaneous manifestations of thyroid disease. J Am Acad Dermatol 1992;26:885–902.
Val I, Almeida G. An overview of lichen sclerosus. Clin Obstet Gynecol 2005;48:808–817.
Dalmau J, Baselga E, Roe E, et al. Psoralen-UVA treatment for generalized prepubertal extragenital lichen sclerosus et atrophicus. J Am Acad Dermatol 2006;55:S56–S58.
Neill SM, Tatnall FM, Cox NH. British Association of Dermatologists. Guidelines for the management of lichen sclerosus. Br J Dermatol 2002;147:640–649.
Meyrick Thomas RH, Ridley CM, McGibbon DH, et al. Lichen sclerosus et atrophicus and autoim-munity—a study of 350 women. Br J Dermatol 1988;118:41–46.
Harrington CI, Dunsmore IR. An investigation into the incidence of autoimmune disorders in patients with lichen sclerosus and atrophicus. Br J Dermatol 1981;104:563–566.
Goolamali EK, Barnes EW, Irvine WJ, et al. Organ-specific antibodies in patients with lichen sclerosus. Br Med J. 1974;4:78–79.
Poskitt L, Wojnarowska F. Lichen sclerosus as a cutaneous manifestation of thyroid disease. J Am Acad Dermatol 1993;28:665.
Wright AJ. Lichen Sclerosus and thyroid disease. J Reprod Med 1998;43:240.
Berger JR, Dobbs MR, Terhune MH, et al. The neurologic complications of scleromyxedema. Medicine 2001;80:313–319.
Maize J, Maize J Jr, Metcalf J. In: Edler DE, Elenitsas R, Johson BL Jr, Murphy GF, eds. Lever's Histopathology of the Skin. 9th ed. Metabolic Diseases of the Skin. Philadelphia: Lippincott Williams and Wilkins; 2005:435–468.
Dinneen AM, Dicken CH. Scleromyxedema. J Am Acad Dermatol 1995;33:37–43.
Pomann JJ, Rudner EJ. Scleromyxedema revisited. Int J Dermatol 2003;42:31–35.
Webster GF, Matsuoka LY, Burchmore D. The association of potentially lethal neurological syndromes with scleromyxedema (papular mucinosis). J Am Acad Dermatol 1993;28:105–108.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer-Verlag London Limited
About this chapter
Cite this chapter
Kirby, J.S., James, W.D. (2008). Dermatologic Disorders Associated with Thyroid Disease. In: Heymann, W.R. (eds) Thyroid Disorders with Cutaneous Manifestations. Springer, London. https://doi.org/10.1007/978-1-84800-187-9_13
Download citation
DOI: https://doi.org/10.1007/978-1-84800-187-9_13
Publisher Name: Springer, London
Print ISBN: 978-1-84800-186-2
Online ISBN: 978-1-84800-187-9
eBook Packages: MedicineMedicine (R0)